دورية أكاديمية
أعرض في EDS

Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study.

التفاصيل البيبلوغرافية
العنوان: Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study.
المؤلفون: Jujić A; Department of Clinical Sciences Malmö, Lund University, Clinical Research Centre, Hämtställe HS 36, Box 50332, 202 13, Malmö, Sweden.; Department of Cardiology, Skåne University Hospital, Inga Marie Nilssons gata 49, 20502, Malmö, Sweden., Atabaki-Pasdar N; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden., Nilsson PM; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden., Almgren P; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.; Lund University Diabetes Centre, Lund University, Malmö, Sweden., Hakaste L; Folkhälsan Research Centre, Biomedicum, Helsinki, Finland.; Research Program Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland.; Department of Endocrinology, Helsinki University Hospital, Helsinki, Finland.; Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland., Tuomi T; Folkhälsan Research Centre, Biomedicum, Helsinki, Finland.; Research Program Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland.; Department of Endocrinology, Helsinki University Hospital, Helsinki, Finland.; Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland., Berglund LM; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.; Lund University Diabetes Centre, Lund University, Malmö, Sweden., Franks PW; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.; Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden.; Department of Nutrition, Harvard School of Public Health, Boston, MA, USA., Holst JJ; Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark., Prasad RB; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.; Lund University Diabetes Centre, Lund University, Malmö, Sweden., Torekov SS; Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark., Ravassa S; Program of Cardiovascular Diseases, CIMA, University of Navarra, Pamplona, Spain.; CIBERCV, Carlos III Institute of Health, Madrid, Spain.; Instituto de Investigación Sanitaria de Navarra (IdisNA), Pamplona, Spain., Díez J; Program of Cardiovascular Diseases, CIMA, University of Navarra, Pamplona, Spain.; CIBERCV, Carlos III Institute of Health, Madrid, Spain.; Instituto de Investigación Sanitaria de Navarra (IdisNA), Pamplona, Spain.; Department of Cardiology and Cardiac Surgery, University of Navarra Clinic, Pamplona, Spain.; Department of Nephrology, University of Navarra Clinic, Pamplona, Spain., Persson M; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden., Melander O; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden., Gomez MF; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.; Lund University Diabetes Centre, Lund University, Malmö, Sweden., Groop L; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.; Lund University Diabetes Centre, Lund University, Malmö, Sweden.; Department of Endocrinology, Helsinki University Hospital, Helsinki, Finland., Ahlqvist E; Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.; Lund University Diabetes Centre, Lund University, Malmö, Sweden., Magnusson M; Department of Clinical Sciences Malmö, Lund University, Clinical Research Centre, Hämtställe HS 36, Box 50332, 202 13, Malmö, Sweden. martin.magnusson@med.lu.se.; Department of Cardiology, Skåne University Hospital, Inga Marie Nilssons gata 49, 20502, Malmö, Sweden. martin.magnusson@med.lu.se.; Wallenberg Center for Molecular Medicine, Lund University, Malmö, Sweden. martin.magnusson@med.lu.se.
المصدر: Diabetologia [Diabetologia] 2020 May; Vol. 63 (5), pp. 1043-1054. Date of Electronic Publication: 2020 Jan 23.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0428 (Electronic) Linking ISSN: 0012186X NLM ISO Abbreviation: Diabetologia Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin Springer Verlag
مواضيع طبية MeSH: Cardiovascular Diseases/*metabolism , Cardiovascular Diseases/*mortality , Gastric Inhibitory Polypeptide/*metabolism , Glucose/*metabolism, Adult ; Aged ; Female ; Genotype ; Glucagon-Like Peptide 1/metabolism ; Humans ; Male ; Middle Aged ; Prospective Studies ; Receptors, Gastrointestinal Hormone/metabolism
مستخلص: Aims/hypothesis: Evidence that glucose-dependent insulinotropic peptide (GIP) and/or the GIP receptor (GIPR) are involved in cardiovascular biology is emerging. We hypothesised that GIP has untoward effects on cardiovascular biology, in contrast to glucagon-like peptide 1 (GLP-1), and therefore investigated the effects of GIP and GLP-1 concentrations on cardiovascular disease (CVD) and mortality risk.
Methods: GIP concentrations were successfully measured during OGTTs in two independent populations (Malmö Diet Cancer-Cardiovascular Cohort [MDC-CC] and Prevalence, Prediction and Prevention of Diabetes in Botnia [PPP-Botnia]) in a total of 8044 subjects. GLP-1 (n = 3625) was measured in MDC-CC. The incidence of CVD and mortality was assessed via national/regional registers or questionnaires. Further, a two-sample Mendelian randomisation (2SMR) analysis between the GIP pathway and outcomes (coronary artery disease [CAD] and myocardial infarction) was carried out using a GIP-associated genetic variant, rs1800437, as instrumental variable. An additional reverse 2SMR was performed with CAD as exposure variable and GIP as outcome variable, with the instrumental variables constructed from 114 known genetic risk variants for CAD.
Results: In meta-analyses, higher fasting levels of GIP were associated with risk of higher total mortality (HR[95% CI] = 1.22 [1.11, 1.35]; p = 4.5 × 10 -5 ) and death from CVD (HR[95% CI] 1.30 [1.11, 1.52]; p = 0.001). In accordance, 2SMR analysis revealed that increasing GIP concentrations were associated with CAD and myocardial infarction, and an additional reverse 2SMR revealed no significant effect of CAD on GIP levels, thus confirming a possible effect solely of GIP on CAD.
Conclusions/interpretation: In two prospective, community-based studies, elevated levels of GIP were associated with greater risk of all-cause and cardiovascular mortality within 5-9 years of follow-up, whereas GLP-1 levels were not associated with excess risk. Further studies are warranted to determine the cardiovascular effects of GIP per se.
References: Int J Epidemiol. 2001 Oct;30 Suppl 1:S30-4. (PMID: 11759848)
Lancet. 2018 Oct 27;392(10157):1519-1529. (PMID: 30291013)
Cell Metab. 2018 Feb 6;27(2):450-460.e6. (PMID: 29275960)
Atherosclerosis. 2015 Apr;239(2):615-21. (PMID: 25746169)
Int J Obes (Lond). 2018 Apr;42(4):826-834. (PMID: 29235553)
JCI Insight. 2017 Nov 2;2(21):. (PMID: 29093273)
Stroke. 2001 May;32(5):1098-103. (PMID: 11340216)
N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
J Clin Endocrinol Metab. 2016 Feb;101(2):485-93. (PMID: 26505824)
Diabet Med. 1998 Jul;15(7):539-53. (PMID: 9686693)
Diabetes. 2016 Jan;65(1):239-54. (PMID: 26395740)
Atherosclerosis. 2003 Oct;170(2):333-7. (PMID: 14612215)
Diabetes. 2011 Sep;60(9):2424-33. (PMID: 21810601)
Diabetologia. 2010 Aug;53(8):1709-13. (PMID: 20454776)
Eur J Heart Fail. 2005 Aug;7(5):787-91. (PMID: 15916919)
Sci Transl Med. 2016 Jun 1;8(341):341ra76. (PMID: 27252175)
Elife. 2018 May 30;7:. (PMID: 29846171)
Epidemiology. 2017 Jan;28(1):30-42. (PMID: 27749700)
N Engl J Med. 2016 Nov 10;375(19):1834-1844. (PMID: 27633186)
Mol Nutr Food Res. 2007 Aug;51(8):1046-52. (PMID: 17624916)
Atherosclerosis. 2014 Oct;236(2):327-37. (PMID: 25128758)
Br J Nutr. 1988 May;59(3):373-80. (PMID: 3293660)
Nat Genet. 2010 Feb;42(2):142-8. (PMID: 20081857)
Pharmacol Rev. 2003 Mar;55(1):167-94. (PMID: 12615957)
Int J Epidemiol. 2017 Dec 1;46(6):1734-1739. (PMID: 28398548)
Nat Genet. 2011 Mar 06;43(4):333-8. (PMID: 21378990)
Circ J. 2016 Aug 25;80(9):1988-97. (PMID: 27375170)
Genome Res. 2011 Jan;21(1):21-32. (PMID: 20978139)
Diabetes. 2013 Jun;62(6):2088-94. (PMID: 23349498)
Endocr Rev. 2016 Dec;37(6):554-583. (PMID: 27732058)
Circ Res. 2018 Feb 2;122(3):433-443. (PMID: 29212778)
Lancet. 2019 Jul 13;394(10193):121-130. (PMID: 31189511)
J Clin Endocrinol Metab. 2016 Apr;101(4):1372-80. (PMID: 26815880)
Am Heart J. 2013 Nov;166(5):823-30.e5. (PMID: 24176437)
معلومات مُعتمدة: Dnr: 2012/1789 International ALF government grants; RD12/0042/0009 International Instituto de Salud Carlos III; FiDiPro grant 263401 and project grant 267882 International Suomen Akatemia; K2011- 65X-20 752- 04 - 6 International Vetenskapsrådet; HOMAGE project grant HEALTH-2012-305507 International European Commission FP7 Programme; 20160872 International Hjärt-Lungfonden
فهرسة مساهمة: Keywords: Cardiovascular; Cardiovascular events; Coronary artery disease; GIP; GLP-1; Glucagon-like peptide 1; Glucose-dependent insulinotropic peptide; Mendelian randomisation; Mortality
المشرفين على المادة: 0 (Receptors, Gastrointestinal Hormone)
59392-49-3 (Gastric Inhibitory Polypeptide)
89750-14-1 (Glucagon-Like Peptide 1)
D6H00MV7K8 (gastric inhibitory polypeptide receptor)
IY9XDZ35W2 (Glucose)
تواريخ الأحداث: Date Created: 20200125 Date Completed: 20210531 Latest Revision: 20210531
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7145777
DOI: 10.1007/s00125-020-05093-9
PMID: 31974732
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0428
DOI:10.1007/s00125-020-05093-9